Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 2, 2012, Pages 127-133

  Lee, Jen Chieh ^a   Lee, Nan Yao ^a   Lee, Hsin Chun ^a,b   Huang, Wei Han ^d   Tsui, Ko Chung ^d   Chang, Chia Ming ^a   Lee, Ching Chi ^a   Chen, Po Lin ^a   Wu, Chi Jung ^c   Hsueh, Po Ren ^d   Ko, Wen Chien ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Community acquired bacteremia; Extended spectrum beta lactamase; Outcomes; UTI

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CLINICAL FEATURE; DISEASE SEVERITY; ESCHERICHIA COLI; FATALITY; FEMALE; HEALTH CARE FACILITY; HOSPITAL; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; URINARY TRACT INFECTION; UROSEPSIS;

ADULT; AGED; AGED, 80 AND OVER; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SEPSIS; TAIWAN; URINARY TRACT INFECTIONS;

EID: 84859817596     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.09.029     Document Type: Article

References (26)

1. Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescenes. Infection 1983, 11:315-317.
2. Peterson D.L., Bonomo R.A. Extended-spectrum β-lactamase: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
3. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Ruíz M., Peña C., et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010, 50:40-48.
4. Pitout J.D., Laupland K.B. Extended-spectrum β-lactamase producing-Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
5. Kang C.I., Cheong H.S., Chung D.R., Peck K.R., Song J.H., Oh M.D., et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2008, 27:85-88.
6. Peña C., Gudiol C., Calatayud L., Tubau F., Domínguez M.A., Pujol M., et al. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect 2008, 68:116-122.
7. Yu W.L., Chuang Y.C. Jan Walther-Rasmussen. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006, 39:264-277.
8. Yang Y.S., Ku C.H., Lin J.C., Shang S.T., Chiu C.H., Yeh K.M., et al. Impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infection. J Microbiol Immunol Infect 2010, 43:194-199.
9. Performance standards for antimicrobial susceptibility testing: 16th informational supplement CLSI document M100-S16 2006, Clinical and Laboratory Standards Institute (CLSI), CLSI, Wayne, PA, USA.
10. Friedman N.D., Kaye K.S., Stout J.E., McGarry S.A., Trivette S.L., Briggs J.P., et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:791-797.
11. Chow J.W., Yu V.L. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999, 11:7-12.
12. Fagon J.Y., Chastre J., Novara A., Medioni P., Gibert C. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med 1993, 19:137-144.
13. Lautenbach E., Patel J.B., Bilker W.B., Edelstein P.H., Fishman N.O. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001, 32:1162-1171.
14. Hsueh P.R., Teng L.J., Chen C.Y., Chen W.H., Yu C.J., Ho S.W., et al. Pandrug-resistant Actinetobacter baumannii causing nosocomial infections in a university hospital. Taiwan. Emerg Infect Dis 2002, 8:827-832.
15. Calbo E., Romani V., Xercavins M., Gómez L., Vidal C.G., Quintana S., et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamase. J Antimicrob Chemother 2006, 57:780-783.
16. Colodner R., Rock W., Chazan B., Keller N., Guy N., Sakran W., et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in non-hospitalized patients. Eur J Clin Microbiol Infect Dis 2004, 23:163-167.
17. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Blood stream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Angents Chemother 2004, 48:4574-4581.
18. Tumbarello M., Sanguinetti M., Montuori E., Trecarichi E.M., Posteraro B., Fiori B., et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51:1987-1994.
19. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Cisneros J.M., Peña C., et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing. Escherichia coli. J Clin Microbiol 2010, 48:1726-1731.
20. Deschamps C., Clermont O., Hipeaux M.C., Arlet G., Denamur E., Branger C. Multiple acquisitions of CTX-M plasmids in the rare D2 genotype of Escherichia coli provide evidence for convergent evolution. Microbiology 2009, 155:1656-1668.
21. Chaubey V.P., Pitout J.D., Dalton B., Ross T., Church D.L., Gregson D.B. Clinical outcome of empirical antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes 2010, 3:116-122.
22. Schwaber M.J., Navon-Venezia S., Schwartz D., Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005, 49:2137-2139.
23. Lautenbach E., Strom B.L., Bilker W.B., Patel J.B., Edelstein P.H., Fishman N.O. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001, 33:1288-1294.
24. Rooney P.J., O'Leary M.C., Loughrey A.C., McCalmont M., Smyth B., Donaghy P., et al. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli. J Antimicrob Chemother 2009, 64:635-641.
25. Reinthaler F.F., Feierl G., Galler H., Haas D., Leitner E., Mascher F., et al. ESBL-producing E. coli in Austrian sewage sludge. Water Res 2010, 44:1981-1985.
26. Rodríguez-Baño J., López-Cerero L., Navarro M.D., Díaz de Alba P., Pascual A. Faecal carriage of extended-spectrum b-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 2008, 62:1142-1149.